secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2026-01-20T23:59:59+00:00
Accession:  0001104659-26-005127
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin seeks SFDA breakthrough designation; QRX003 could be first approved Netherton treatment in 2H2026
--------------------------------------------------------------------------------

- Filed application with Saudi FDA for Breakthrough Medicine Designation for QRX003 for Netherton Syndrome.
- If granted, QRX003 could be approved for sale/reimbursement in Saudi Arabia by 2H 2026, first-ever approved treatment for Netherton Syndrome.
- Two pivotal trials for QRX003 lotion (4%) enrollment expected to complete 1H 2026; top-line data in 2H 2026.
- NDA submission planned in US and other territories in late 2026/early 2027, subject to clinical outcomes.
- As of Jan 20, 2026, Quoin has 1,616,179 ADSs outstanding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465926005127/0001104659-26-005127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465926005127/tm263667d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-005127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer